US EditionPublished • loading... • Updated
FDA Drug Recalls and Warnings: Recalls for Compounded Semaglutide and Tirzepatide, Wegovy; Facility Warning Letters - MedShadow Foundation | Independent Health & Wellness Journalism
Summary by MedShadow
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
FDA Drug Recalls and Warnings: Recalls for Compounded Semaglutide and Tirzepatide, Wegovy; Facility Warning Letters - MedShadow Foundation | Independent Health & Wellness Journalism
Welcome to the FDA Recalls and Warnings Update, a series dedicated to keeping you informed about the latest medication recalls, manufacturing violations, and quality concerns affecting your prescriptions. In this installment, we’re highlighting three recalls for compounded semaglutide and tirzepatide and one recall for the GLP-1 brand-name drug Wegovy (tirzepatide). Semaglutide is the active ingredient in Ozempic (for type 2 diabetes) and Wegovy…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
